GOVX (GeoVax Labs Inc.) stock: $0.16, $1.9M market cap, $3.1M cash, -$1.2M EV, $2.6M fully diluted market cap. Lead program: COVID-19 Vaccine (COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
MINE SAFETY DISCLOSURES 27 PART II 28 ITEM 5. MARKET FOR REGISTRANT ’ S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 28 ITEM 6. RESERVED 28 ITEM 7.
Status note Company's primary near-term strategic priority. EMA scientific advice received May 2025. cGMP clinical drug substance batch produced; continuous avian cell line manufacturing platform under development.
Partnerships BARDA (via Rapid Response Partnership Vehicle consortium): award Jun 2024 to advance GEO-CM04S1 Phase 2b trial
Indications
COVID-19(Phase 2)
Status note Discontinued May 26, 2026 as part of strategic reprioritization (not safety-related); BARDA contract terminated for convenience in April 2025.
Per-asset detail extracted from the 10-Q filed 2026-07-27. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
COVID-19 Vaccine
Lead indication
COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia
COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.